LITTLE FALLS, N.J.,
March 17, 2016 /PRNewswire/
-- CANTEL MEDICAL CORP. (NYSE: CMN) announced today
that consistent with its long-term succession plan, Jorgen B. Hansen, Cantel's President and Chief
Operating Officer will become President and Chief Executive Officer
as well as become a member of the Board of Directors on
August 1, 2016. Andrew A. Krakauer will step down from the CEO
role and as a Director on July 31,
2016 and serve as a Senior Advisor until October 15, 2016.
Charles M. Diker, Cantel's
Chairman of the Board stated, "Cantel has a detailed succession
planning process. Our CEO succession plan included hiring
Jorgen Hansen almost 3½ years ago.
Jorgen has been responsible for all day-to-day operations of the
Company since he joined Cantel as COO and was one of the key
architects of our strategic plan including our international
expansion. Jorgen has also been integral to our great success over
the past three years completing numerous acquisitions and then
leading their successful integration into Cantel. We have great
confidence that he is well prepared to lead the Company on its
current successful course as its next Chief Executive Officer."
Mr. Hansen joined Cantel in November
2012 as EVP and COO and was promoted to President and COO in
November 2014. He also served as the senior executive of our
Endoscopy business, the Company's largest segment, from when he
started until July 2015. Prior to
joining Cantel, Mr. Hansen was in global leadership positions with
increasing responsibility within the healthcare and medical device
industry for over fifteen years. He was Senior Vice President,
Global Marketing, Business Development, Science and Innovation for
ConvaTec Corp. Prior to that, he held leadership roles in
Asia and Europe, ranging from General Manager, Division
Head and Senior Vice President of Global Operations for Coloplast
A/S. Mr. Hansen received his BS Degree in Mechanical Engineering
from Denmark Technical University, and an International Commerce
degree from the Copenhagen Business School in Denmark.
Mr. Diker added, "Andy Krakauer
helped Cantel achieve unprecedented success during his 11½ year
tenure. Andy initially served as COO before being appointed
President in 2008 and CEO in 2009. Under his leadership as Cantel's
senior executive for the past eight years, the Company has become a
recognized global leader in infection prevention while delivering
impressive returns to our shareholders. We thank Andy for his
tremendous leadership and service to Cantel."
Mr. Krakauer added, "It has been a great honor to serve as the
leader of Cantel. I am very proud of the executive team we have
assembled over the past few years and I am extremely confident that
we have the management now in place to run a company multiple times
our current size. I strongly support Jorgen's promotion to CEO
effective August 1, 2016 and look
forward to a smooth transition over the next five months and to
serving as a senior advisor and consultant to the Company beyond
that."
Cantel Medical is a leading global company dedicated to
delivering innovative infection prevention and control products and
services for patients, caregivers, and other healthcare providers
which improve outcomes, enhance safety and help save lives.
Our products include specialized medical device reprocessing
systems for endoscopy and renal dialysis, advanced water
purification equipment, sterilants, disinfectants and cleaners,
sterility assurance monitoring products for hospitals and dental
clinics, disposable infection control products primarily for dental
and GI endoscopy markets, dialysate concentrates, hollow fiber
membrane filtration and separation products, and specialty
packaging for infectious and biological specimens. Additionally, we
provide technical service for our products.
For further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cantel-medical-announces-ceo-succession-300237713.html
SOURCE Cantel Medical Corp.